HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
FULC
Fulcrum Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $495.5M
Market Cap
$495.5M
Enterprise Val
$166.9M
P/E Ratio
-6.51
P/B Ratio
1.49
Trailing PEG (1Y)
0.61
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$333.3M
Return on Equity-27.80%
Return on Assets-26.32%
Current Ratio34.33
Debt/Equity0.02
LT Debt/Equity0.01
Revenue Per Share0.00

Income Statement

Mar 31, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$14.1M
SG&A$8.1M
Operating Expenses$22.2M
Operating Income-$22.2M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$18.9M
EPS (Basic)$-0.25
EPS (Diluted)$-0.25
EBIT-$18.9M
EBITDA-$18.6M
Consolidated Income-$18.9M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$51.5M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$338.7M
LT Investments$0.00
Property, Plant & Equipment$6.4M
Intangibles$0.00
Non-Current Assets$8.1M
Total Assets$346.8M
Accounts Payable$2.5M
Current Debt$2.5M
Current Liabilities$9.9M
LT Debt$3.4M
Non-Current Liabilities$3.6M
Total Liabilities$13.5M
Total Debt$5.9M
Retained Earnings-$613.2M
Shareholder Equity$333.3M
Shares Outstanding66,600,209

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$18.8M
Investing Cash Flow-$128.2M
Financing Cash Flow-$312.0K
CapEx-$8.0K
Free Cash Flow-$18.8M
Depreciation & Amort.$338.0K
Stock-Based Comp$3.9M
Acquisitions / Disposals$0.00
Investment Activity-$128.2M
Debt Issued/Repaid$0.00
Equity Issued/Repaid-$312.0K
Dividends Paid$0.00
Net Change in Cash-$147.3M
Data cached · Meta live · Daily live · Statements live · TTL 24h